Viracta: An Open-Label, Phase 2 Trial of Nanatinostat in Combination with Valganciclovir in Patients with Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas (NAVAL-1)
Clinical Trial Grant
Administered By
Duke Cancer Institute
Awarded By
Viracta Therapeutics, Inc.
Start Date
September 22, 2023
End Date
September 4, 2028
Administered By
Duke Cancer Institute
Awarded By
Viracta Therapeutics, Inc.
Start Date
September 22, 2023
End Date
September 4, 2028